Wolverine: Two Repair Peptides, One Untested Combination

The short version

The Wolverine blend is a research-community pairing of two peptides: BPC-157 and TB-500. It is not a single chemical compound but a co-formulated combination sold by research suppliers, sometimes in a single vial. The rationale is that the two peptides work through different, non-overlapping repair mechanisms — BPC-157 encourages new blood vessels to grow into damaged tissue via the VEGFR2 pathway ^[4], while TB-500 (via its parent protein thymosin beta-4) regulates the actin skeleton that cells use to crawl toward a wound ^[10].

Here is the honest framing: no peer-reviewed study has tested BPC-157 and TB-500 together in a controlled experiment. Every claim about the blend's effect in humans is extrapolated from each peptide's independent, overwhelmingly preclinical record. Both components are WADA-prohibited, neither is an approved drug, and no human dose is listed on this page.

What it is

Wolverine is not a single molecule. It is a co-formulation of two distinct synthetic peptides:

1. BPC-157 — a fifteen-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; ~1419.5 Da) derived from a protein in human gastric juice.
2. TB-500 — a synthetic N-acetylated heptapeptide (Ac-LKKTETQ; ~889.0 Da) corresponding to the actin-binding region (residues 17-23) of thymosin beta-4.

The blend has no single CAS number or molecular weight. Research suppliers commonly offer it as a single reconstituted vial. The two peptides are co-dissolved, not chemically bonded, and their individual pharmacokinetics differ: BPC-157 has an elimination half-life under 30 minutes ^[3], while TB-500 and its parent protein behave differently — a pharmacokinetic mismatch that makes "simultaneous effect" claims complicated.

How it is supposed to work

The Wolverine rationale is a two-pathway story. BPC-157 is described as the angiogenic half: in animal and cell models it upregulates the VEGFR2 vessel-growth receptor and activates the downstream VEGFR2-Akt-eNOS pathway, encouraging blood-vessel formation and restoring circulation to ischemic tissue ^[4]. TB-500 (with the important caveat that evidence comes mostly from full-length thymosin beta-4, not the fragment) is described as the cell-migration half: it sequesters monomeric actin 1:1 via the LKKTETQ motif, regulating the cytoskeletal dynamics that drive cells toward a wound, reduce scarring, and recruit progenitors ^[10].

The blend's marketing positions these as complementary arms of the same cascade — grow a blood supply in, then fill in the wound. The theory is internally consistent. The problem is that it is purely theoretical for the combination: no controlled head-to-head or co-administration study exists that would define a synergistic dose, ratio, or endpoint for the two given together.

What the research shows

The state of the blend evidence. A 2025 systematic review of BPC-157 in orthopaedic sports medicine covered 36 studies (35 preclinical, only one human — a 12-patient retrospective intra-articular knee-pain report). It found no clinical safety data and reached a level IV-V (lowest-tier) evidence conclusion for BPC-157 alone; it makes no mention of TB-500 or any combination ^[23]. That is the clearest published statement that the Wolverine combination has no controlled clinical evidence.

BPC-157 component. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, rigorous large-scale trials are lacking, and the peptide should be treated as investigational ^[2]. The 2017 VEGFR2 mechanistic study establishes the angiogenic mechanism for BPC-157's component contribution ^[4].

TB-500 component. A 2026 Sports Medicine review of unapproved peptides for musculoskeletal injury — listing both BPC-157 and TB-500/thymosin beta-4 — concludes that animal-model promise has not been matched by rigorous human safety data, and that these compounds operate largely outside regulatory oversight ^[8]. The thymosin beta-4 mechanism review consolidates the actin-migration rationale for TB-500's component contribution ^[10].

Reported effects, cautions & safety

The blend inherits and compounds the cautions of both components:

• No combination study. No peer-reviewed study has tested BPC-157 and TB-500 together. "Synergy" is mechanistic extrapolation, not direct evidence ^[23][2].
• TB-500 identity caveat. The "TB-500" fragment sold in the blend is Ac-LKKTETQ (~889 Da), but most efficacy data come from full-length thymosin beta-4 (~4,963 Da). The blend inherits this gap ^[8].
• Both components are overwhelmingly preclinical. BPC-157 has three small human pilots ^[2]; the TB-500 fragment has zero completed controlled human trials ^[8].
• Tumor angiogenesis signal. Both BPC-157 (via VEGFR2) and thymosin beta-4 are pro-angiogenic. Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis; the same pro-repair properties could theoretically support tumor growth ^[10].
• Both components are WADA-prohibited. Using either or both in an athletic context implicates anti-doping rules ^[8].
• Unregulated supply. Product identity, purity and the actual ratio of BPC-157 to TB-500 in any given vial are unverified outside formal studies.

The KLOW blend on this site adds GHK-Cu and KPV to this pairing. Community members report both benefits and adverse effects for KLOW — those are described on the KLOW page.

Where it fits in recovery research

Wolverine sits at the intersection of the two most-studied repair peptides on this site. It is the blend that put BPC-157 and TB-500 together in the research-use community, and it is the conceptual core of the larger KLOW blend. Its two-mechanism rationale is coherent and the individual components have real preclinical depth — the honest caveat is that the combination itself has never been tested. That gap is not unusual in peptide research, but it is worth holding clearly. See the compare page to see how all six line up.